Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Blood (2024) 144 (Supplement 1): 470.

https://doi.org/10.1182/blood-2024-199723

Published: 2024

Journal Articles

Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

Devang Thakkar, Brian T. Hill, Rachel Kositsky, Shari Tian, Leonardo Biral, Veronica Russell, Tushar Dave, Cassandra L. Love, Caroline Roth, Matthew Stuart McKinney, Ahmed Galal, Jadee Neff, Agrima Mian, Ellen Kendall, Sarah L. Ondrejka, Matthew Chiaramonte, Govind Bhagat, Kenneth N. Ofori, Ran Reshef, Alexandra E. Kovach, Tarsheen Sethi, Emily F. Mason, Shakthi Bhaskar, Olalekan O. Oluwole, Chad McCall, Christopher Pallas, Nilanjan Ghosh, Robert Ferdman, George Chen, Francisco Hernandez-Ilizaliturri, Joanna Zurko, Ashley Cunningham, Nirav C Shah, Boyu Hu, Deborah M. Stephens, Monalisa Ghosh, Neil Bailey, Krish Patel, John M. Pagel, Kavya Kannamma Kannan, Eric D. Hsi, Rakhee Vaidya, Andrew Ip, Andre Goy, Swetha Kambhampati, Robert Ohgami, Charalambos Andreadis, Christian A Gordillo, Brianna Just, Jonathon B Cohen, Arielle Baim, Julie Barbello, Erika Cavallone, Veronika Bachanova, Maureen Laschen, Andinet Teferra, Frederique Lorcy, Sylvain Lamure, Guillaume Cartron, Valerie Dardalhon, Kikkeri N Naresh, Magdalena Czader, Anupama Reddy, Elizabeth Thacker, Clayton Parker, Lanie Happ, Sandeep Dave

Blood (2024) 144 (Supplement 1): 3409.

https://doi.org/10.1182/blood-2024-199758

Published: 2024

Journal Articles

Favorable Safety Profile and Durable Responses to Pmb-CT01 (BAFFR-CAR T Cell) Therapy in Patients with B-Cell Lymphomas Ineligible for or Who Failed CD19-Targeted Therapy, Including CD19-Negative Disease

Marissa Morales Del Real, John H. Baird, Lu Chen, Joo Y. Song, Xiuli Wang, Swetha Kambhampati, Alan Macias, Emanuela C Marcucci, Soungchul Cha, Zhenyuan Dong, Teresa Kim, Baishakhi Barva, Sandrine Puverel, Qing Liu-Michael, Hazel Ting-Ying Cheng, Stephen J. Forman, Larry W. Kwak, Lihua E. Budde

Blood (2024) 144 (Supplement 1): 3127.

https://doi.org/10.1182/blood-2024-198416

Published: 2024

Journal Articles

Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Blood (2024) 144 (Supplement 1): 526.

https://doi.org/10.1182/blood-2024-199139

Published: 2024

Journal Articles

Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma

Blood (2024) 144 (Supplement 1): 524.

https://doi.org/10.1182/blood-2024-198749

Published: 2024

Journal Articles

Brentuximab Vedotin-Based Regimens for Older Patients with Newly Diagnosed Classical Hodgkin Lymphoma - International, Multi-Center Real-World Experience

Efrat Luttwak, Swetha Kambhampati, Esther Drill, Nivetha Ganesan, Liron Hofstetter, Ronit Gurion, Shlomzion Aumann, Arnon Haran, Mika Geva, Marc Panossian, Robert Stuver, Paul A. Hamlin, Ariela Noy, Alex F. Herrera, Alison Moskowitz

Blood (2024) 144 (Supplement 1): 1668.

https://doi.org/10.1182/blood-2024-212085

Published: 2024

Journal Articles

Devimistat Results in a Low Complete Remission Rate in Heavily Pre-Treated Burkitt Lymphoma

Raphael Steiner, Liana Nikolaenko, Swetha Kambhampati, Niloufer Khan, Ranjit Nair, Jeremy S. Abramson, Steven Horwitz, Matthew Matasar, Colette Owens, Ildefonso Ismael Rodriguez Rivera, David J. Straus, Timothy S Pardee, Sanjeev Luther, Win Su Thet, Shreya Vemuri, Ariela Noy

Blood (2024) 144 (Supplement 1): 1729.

https://doi.org/10.1182/blood-2024-202459

Published: 2024

Journal Articles

The Clinical Impact and Cost-Effectiveness of PET-Based and Ctdna-Based Evaluation at End-of-Therapy after Frontline Treatment of DLBCL

Swetha Kambhampati, Jordan S Goldstein, Seth Buller, Mark Roschewski, Ash A. Alizadeh, Nikhil Thiruvengadam

Blood (2024) 144 (Supplement 1): 2276.

https://doi.org/10.1182/blood-2024-203873

Published: 2024

Journal Articles

Healthcare Resource Utilization and Costs to Patients and Payers Among Real-World Patients with Follicular Lymphoma in the US Treated with Tazemetostat Compared to Other Standard-of-Care Therapies

Syvart Dennen, Allison Dillon, Paul Cockrum, Swetha Kambhampati

Blood (2024) 144 (Supplement 1): 7626.

https://doi.org/10.1182/blood-2024-203592

Published: 2024

Journal Articles

A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 1742.1.

https://doi.org/10.1182/blood-2024-198727

Published: 2024

Journal Articles

Trial in Progress: Open-Label Phase 1 Study to Evaluate Safety of SGN-35C in Adults with Select Relapsed/Refractory Lymphomas (SGN35C-001)

Alex F. Herrera, Swetha Kambhampati, Michael A Spinner, Christina Poh, Elizabeth H. Phillips, Vincent Ribrag, Ming Jin Yan, Tara Chen, Julie M. Vose

Blood (2024) 144 (Supplement 1): 1674.1.

https://doi.org/10.1182/blood-2024-194011

Published: 2024

Journal Articles

Changes in Treatment Patterns over Time Among Real-World Patients with Follicular Lymphoma at Predominantly Community Facilities in the US

Swetha Kambhampati, Allison Dillon, Paul Cockrum, Syvart Dennen

Blood (2024) 144 (Supplement 1): 3654.

https://doi.org/10.1182/blood-2024-203750

Published: 2024

Journal Articles

Hematologic Toxicity Among Real-World US Patients with Follicular Lymphoma Treated with Tazemetostat Compared to Other Standard-of-Care Therapies

Syvart Dennen, Allison Dillon, Paul Cockrum, Swetha Kambhampati

Blood (2024) 144 (Supplement 1): 7759.

https://doi.org/10.1182/blood-2024-203752

Published: 2024

Journal Articles

Serious Adverse Drug Reactions (sADRs) Involving Hematology and Resulting in Black Box Warnings or FDA Non-Approval: Results from the First Quarter Century of RADAR/Sonar

Blood (2024) 144 (Supplement 1): 3638.

https://doi.org/10.1182/blood-2024-206590

Published: 2024

Journal Articles

Comparative Effectiveness of Axicabtagene Ciloleucel Vs Historical Standard-of-Care in Patients with Relapsed or Refractory Follicular Lymphoma: An Analysis of CIBMTR and SCHOLAR-5 Data

Blood (2023) 142 (Supplement 1): 2121.

https://doi.org/10.1182/blood-2023-178629

Published: 2023

Journal Articles

The Combination of Nivolumab and CC-486 Is Active in Hodgkin Lymphoma Refractory to PD-1 Blockade

Matthew G. Mei, Lu Chen, Sandrine Puverel, L. Elizabeth Budde, Swetha Kambhampati, Shari Daniels, Bev Dunning, Melissa Banez, Larry W. Kwak, Alex F. Herrera

Blood (2023) 142 (Supplement 1): 1697.

https://doi.org/10.1182/blood-2023-190753

Published: 2023

Journal Articles

Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma

Swetha Kambhampati, Reid W. Merryman, Yan Wang, Evandro Bezerra, Timothy Voorhees, Ayo S Falade, Madhav R Seshadri, Megumi Bailey, Neil Bailey, Krish Patel, Charalambos Andreadis, Adam S Kittai, Caron A Jacobson, Joycelynne Michelle Palmer, Annette Brown, Alex F. Herrera, L. Elizabeth Budde

Blood (2023) 142 (Supplement 1): 3511.

https://doi.org/10.1182/blood-2023-182467

Published: 2023

Journal Articles

Promising Safety and Anti-Lymphoma Efficacy of Autologous Pmb-CT01 (BAFFRCAR T Cell) Therapy in a First-in-Human Phase 1 Study

L. Elizabeth Budde, Marissa Morales Del Real, John H. Baird, Lu Chen, Joo Y. Song, Swetha Kambhampati, Alan Macias, Teresa Kim, Sylvia Dulan, Baishakhi Barva, Sandrine Puverel, Katrin Tiemann, Hazel Ting-Ying Cheng, Stephen J. Forman, Larry W. Kwak

Blood (2023) 142 (Supplement 1): 221.

https://doi.org/10.1182/blood-2023-183032

Published: 2023

Journal Articles

Real-World Outcomes of Brexucabtagene Autoleucel (Brexu-cel) for Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL): A CIBMTR Subgroup Analysis of High-Risk Characteristics

Blood (2023) 142 (Supplement 1): 107.

https://doi.org/10.1182/blood-2023-179269

Published: 2023

Journal Articles

Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Hodgkin Lymphoma across the United States

Blood (2023) 142 (Supplement 1): 3071.

https://doi.org/10.1182/blood-2023-174589

Published: 2023

NARROW

Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

Favorable Safety Profile and Durable Responses to Pmb-CT01 (BAFFR-CAR T Cell) Therapy in Patients with B-Cell Lymphomas Ineligible for or Who Failed CD19-Targeted Therapy, Including CD19-Negative Disease

Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma

Brentuximab Vedotin-Based Regimens for Older Patients with Newly Diagnosed Classical Hodgkin Lymphoma - International, Multi-Center Real-World Experience

Devimistat Results in a Low Complete Remission Rate in Heavily Pre-Treated Burkitt Lymphoma

The Clinical Impact and Cost-Effectiveness of PET-Based and Ctdna-Based Evaluation at End-of-Therapy after Frontline Treatment of DLBCL

Healthcare Resource Utilization and Costs to Patients and Payers Among Real-World Patients with Follicular Lymphoma in the US Treated with Tazemetostat Compared to Other Standard-of-Care Therapies

A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Trial in Progress: Open-Label Phase 1 Study to Evaluate Safety of SGN-35C in Adults with Select Relapsed/Refractory Lymphomas (SGN35C-001)

Changes in Treatment Patterns over Time Among Real-World Patients with Follicular Lymphoma at Predominantly Community Facilities in the US

Hematologic Toxicity Among Real-World US Patients with Follicular Lymphoma Treated with Tazemetostat Compared to Other Standard-of-Care Therapies

Serious Adverse Drug Reactions (sADRs) Involving Hematology and Resulting in Black Box Warnings or FDA Non-Approval: Results from the First Quarter Century of RADAR/Sonar

Comparative Effectiveness of Axicabtagene Ciloleucel Vs Historical Standard-of-Care in Patients with Relapsed or Refractory Follicular Lymphoma: An Analysis of CIBMTR and SCHOLAR-5 Data

The Combination of Nivolumab and CC-486 Is Active in Hodgkin Lymphoma Refractory to PD-1 Blockade

Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma

Promising Safety and Anti-Lymphoma Efficacy of Autologous Pmb-CT01 (BAFFRCAR T Cell) Therapy in a First-in-Human Phase 1 Study

Real-World Outcomes of Brexucabtagene Autoleucel (Brexu-cel) for Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL): A CIBMTR Subgroup Analysis of High-Risk Characteristics

Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Hodgkin Lymphoma across the United States

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only